We’re proud to introduce PhenoScout AI, our next-generation multiplex immunofluorescence (mIF) analysis solution.
By automating phenotype identification, biomarker quantification, and spatial readouts, PhenoScout AI reduces variability and supports large-scale studies. The solution is designed for pharma, diagnostics, and academic research to accelerate translational medicine.
👉 Learn more
‍
CellCarta has launched the Digital Pathology & AI Consortium, bringing together leading companies at the intersection of AI and pathology to advance drug development. Mindpeak is proud to be among the founding members.
The consortium is built on a core premise: AI in pathology only delivers value when it is embedded in strong laboratory infrastructure, clinical workflows, and deep pathology expertise. By combining these capabilities across member organizations, the group aims to generate robust, reproducible insights that support precision medicine at scale.
‍
We are pleased to announce that Mindpeak will be exhibiting at AACR 2026 in collaboration with Revolune.
At this year’s meeting, we will present a joint approach to simplifying spatial biology workflows by combining Revolune’s multiplex immunofluorescence (mIF) reagents with Mindpeak’s AI-powered image analysis - PhenoScout.
By integrating staining and analysis into a streamlined workflow, researchers can generate high-quality multiplex tissue data and efficiently derive meaningful biological insights. This supports key applications such as biomarker discovery and translational cancer research.
We believe that reducing complexity is essential to accelerating the adoption of spatial biology technologies. Together with Revolune, our goal is to make advanced multiplex workflows more accessible, scalable, and practical for real-world use.
For more details, please read the full press release:
https://lnkd.in/dSRZaEAw
If you are attending AACR 2026, we invite you to visit us at booth #1660
We are excited to announce a global reseller agreement with Leica Biosystems, a Danaher company and global leader in digital pathology. This partnership marks an important step in expanding access to Mindpeak’s AI-powered pathology solutions worldwide.
By integrating our AI applications into the Aperio HALO AP platform and Aperio AI Store, laboratories and biopharma teams can seamlessly bring advanced biomarker and tissue analysis into their daily workflows -supporting greater efficiency, reproducibility, and scalability.
Together, we aim to accelerate biomarker discovery and enable smarter decisions across the drug development lifecycle.
Read the full Press Release here: https://www.einpresswire.com/article/900262524/mindpeak-announces-global-reseller-agreement-with-leica-biosystems-to-expand-access-to-ai-pathology-solutions
Connect with our team to explore how precision pathology works in your setting